New Experimental Therapeutics

NEXT Oncology is a leading global network of Phase I clinical trial sites specializing in the development of innovative anticancer therapies. Founded by Dr. Anthony Tolcher, the organization is dedicated to providing advanced cancer patients with access to the latest experimental treatments through first-in-human and early-phase clinical trials. The company operates a network of specialized research centers across the United States, Spain, and Japan, collaborating with major pharmaceutical and biotechnology sponsors to accelerate drug development. In 2025, NEXT Oncology was acquired by IQVIA and integrated into the Avacare Clinical Research Network, significantly expanding its global reach and operational capabilities. The organization is recognized for its expertise in complex Phase I trial design, biomarker-driven patient matching, and rapid enrollment strategies.